32 results about "SIGLEC" patented technology

The invention relates to the technical field of biomedical materials, in particular to engineered small extracellular vesicle hydrogel enriched with PD-L1 and Siglec-15 as well as a preparation method and application of the engineered small extracellular vesicle hydrogel. The engineering small extracellular vesicle hydrogel is enriched with PD-L1 and Siglec-15 at the same time, the engineering small extracellular vesicle hydrogel comprises a hydrogel base body and PDL1-Siglec15-sEVs loaded in the hydrogel base body, and the PDL1-Siglec15-sEVs are small extracellular vesicles with the PD-L1 and the Siglec-15 in an overexpression mode. Compared with natural small extracellular vesicles and a traditional wound surface treatment strategy, the engineered small extracellular vesicle hydrogel has the advantages that PD-L1 and Siglec-15 can be enriched in the vesicles, so that more accurate immune microenvironment regulation and control can be realized on the local part of a wound surface, excessive inflammatory response is moderately inhibited, phenotype transformation of macrophages to be beneficial to tissue regeneration is promoted, and the wound surface treatment effect is improved. The hydrogel is used as a carrier and can provide a moist healing environment and a three-dimensional scaffold structure, so that the residence time of the engineered small extracellular vesicles on the local wound surface is remarkably prolonged, and slow release is realized.

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

Provided herein are anti-Siglec-10 and Siglec-8 antibody compositions and combinations thereof, and their use in the treatment of neurodegenerative diseases.

The present application relates to the technical field of biomedical materials, in particular to an engineered small extracellular vesicle hydrogel enriched with PD-L1 and Siglec-15, and a preparation method and application thereof. The engineered small extracellular vesicle hydrogel is simultaneously enriched with PD-L1 and Siglec-15, and comprises a hydrogel matrix and PDL1-Siglec15-sEVs loaded in the hydrogel matrix, wherein the PDL1-Siglec15-sEVs are small extracellular vesicles overexpressing PD-L1 and Siglec-15. Compared with natural small extracellular vesicles and traditional wound treatment strategies, the engineered small extracellular vesicle hydrogel of the present application can realize more precise immune microenvironment regulation at the local wound by enriching PD-L1 and Siglec-15 in the vesicles, moderately inhibit excessive inflammatory response, promote the phenotype transformation of macrophages to a phenotype conducive to tissue regeneration, help smooth transition from the inflammatory stage to the proliferation and reconstruction stage, and the hydrogel as a carrier can provide a moist healing environment and a three-dimensional scaffold structure, significantly prolong the residence time of the engineered small extracellular vesicles at the local wound, and realize slow release.

The invention belongs to the technical field of biological pharmacy, and particularly discloses a Siglec-15 affinity peptide and application thereof. According to the invention, a phage display heptapeptide library high-throughput screening technology is adopted, Siglec-15 affinity peptide 7-8 is obtained through multiple rounds of screening, and the Siglec-15 affinity peptide 7-8 is optimized and modified to obtain a reversed sequence flip peptide d-7-8. Experimental results show that the Siglec-15 affinity peptide can be used for affinity of Siglec-15 protein and blocking the interaction between Siglec-15 and a ligand Sialyl-Tn of Siglec-15, so that the anti-tumor effect is achieved; an in-vitro cell level experiment shows that the Siglec-15 affinity peptide has a relieving effect on inhibition of Siglec-15 on CD8 + T cell proliferation, has an obvious immune activation effect, does not have obvious toxic or side effects, can be used for preparing an anti-tumor drug or a detection reagent taking Siglec-15 as a target spot, and has a relatively good medical application prospect.

The present invention provides anti-Siglec-9 antibodies and antigen-binding fragments thereof as well as isolated nucleic acids, vectors, engineered cells, formulations thereof, and methods of use thereof for treating diseases including cancer and bone disease in a human subject. The invention is further directed to bispecific and multispecific antibodies, antibody-drug conjugates and chimeric antigen receptors derived from the anti-Siglec-9 antibodies and fragments thereof.

The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

To provide pigs that exhibit resistance to porcine reproductive respiratory syndrome virus (PRRSV). [Solution] This disclosure relates to a genetically modified pig in which at least one allele of the SIGLEC-1 gene is inactivated and / or at least one allele of the CD163 gene is inactivated. A genetically modified pig in which both alleles of the SIGLEC-1 gene and / or both alleles of the CD163 gene are inactivated is resistant to porcine reproductive respiratory syndrome virus (PRRSV). Methods for producing such transgenic pigs are also provided.

Anti-Siglec-9 antibody molecules or binding fragments thereof are disclosed. These anti-Siglec-9 antibody molecules or binding fragments can be used to treat cancer, acute or chronic hepatitis B.

Undesired mast cell activities are linked with various diseases or disorders, such as allergies, inflammatory diseases, autoimmune diseases, and cancers. There remains a need for new and improved therapeutics (e.g., for mast cell associated diseases or disorders) that can target c-Kit and / or siglec-6. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6.

This invention discloses a Siglec15-specific blocking peptide and its applications, relating to the field of biopharmaceutical technology. The specific blocking peptide is the following polypeptide or its modified form: (1) a polypeptide with the amino acid sequence shown in SEQ ID NO: 2; (2) a polypeptide with the amino acid sequence shown in SEQ ID NO: 21. This invention provides a Siglec-15-specific blocking peptide, which has a strong affinity for Siglec-15 protein, can efficiently block the interaction between Siglec-15 and its ligand Sialyl-Tn, and exhibits good serum stability and low toxicity; it also provides polypeptide probes, related reagents, drugs, and applications of this blocking peptide.

The present invention provides natural killer engagers specific for activating natural killer cells through binding to Siglec-7, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

An anti-Siglec-15 antibody and a use thereof, specifically, an isolated anti-Siglec-15 antibody or antigen-binding fragment thereof, an expression vector and host cell for expressing the antibody or antigen-binding fragment thereof, and a use of the antibody or antigen-binding fragment and a pharmaceutical composition containing the antibody or antigen-binding fragment thereof, and a use of the pharmaceutical composition.

The invention provides a rheumatoid arthritis biomarker as well as a screening method, application and a kit, and the rheumatoid arthritis biomarker is AXL + SIGLEC-6 + dendritic cells (AS DC for short). According to the invention, AS DC can be used as a specific marker for evaluating the disease activity of RA for the first time, and the disease activity of RA can be effectively measured.

The invention provides a preparation method of in-vitro sialic acid-calcium ion self-assembled nanoparticles (SA-CaNPs), and relates to the technical fields of organic chemistry, biological medicine nanometer, molecular biology and the like. The nanoparticles are formed by self-assembly of sialic acid derivatives (preferably N-acetylneuraminic acid) and divalent calcium ions, and the particle size is 300-500 nm. The preparation method comprises the following steps: mixing a sialic acid solution with a calcium chloride solution, stirring and self-assembling without an organic solvent or a surfactant. The SA in the particle can be naturally combined with a Siglecc receptor highly expressed by a tumor / brain, so that the active targeting property of the medicine is expected to be improved; ca < 2 + > is dissociated in a lysosome acidic environment (pH 5.0), and can respond to release of drugs. The nanoparticles formed by self-assembly of the two have wide application prospects in the field of drug loading.

The invention relates to the technical field of biological medicines, in particular to a responsive RNA (Ribonucleic Acid) delivery system for brain glioma as well as a preparation method and application of the responsive RNA delivery system. Through fusion of blood-brain barrier penetrating peptide ANG-2 mediated cross-blood-brain barrier delivery and combination of Siglec-15 mediated immune targeting recognition, a dual targeting mechanism is constructed, a delivery system can be guided to accurately recognize a glioma focus, the enrichment amount of the delivery system in a focus area is remarkably increased, a foundation is laid for playing a role of a nucleic acid drug, and the application prospect is broad. The targeting and effectiveness of treatment are effectively improved, and damage to normal brain tissues is avoided. A dual stimulation release mechanism of acid response and active oxygen response can accurately respond to glioma focuses and endogenous stimulation in cells. Through the synergistic compatibility of the G0-C14 carrier and the charge reversal polylysine, the loading efficiency of the YTHDF2 siRNA is effectively improved, and meanwhile, the cycling stability of the nucleic acid medicine in vivo is enhanced.

The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and / or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9 ECD or Siglec-9 ECD fusion molecule, for example by determining the level of CD163 and / or Siglec-9, and in some embodiments also CD68 and / or sialic acid expression in tumor or immune cells.

Provided are an anti-Siglec-8 antibody or antigen-binding fragment, the use thereof in the preparation of a drug for treating a condition mediated by eosinophils and / or mast cells, and a composition and kit containing the anti-Siglec-8 antibody or antigen-binding fragment.

The present disclosure provides for engineered protein constructs, compositions, and uses thereof for treating diseases. The engineered protein constructs and compositions comprising a first antigen-binding moiety that binds Sialic acid–binding immunoglobulin-like lectin 8 (SIGLEC-8) and a second antigen-binding moiety that binds CD117.

Disclosed herein is generally directed to antibodies against the Siglec-3, and pharmaceutical compositions that comprise the antibodies. According to some embodiments of the present disclosure, the present anti-Siglec-3 antibodies may suppress the over activation of Siglec-3, thereby reversing the immunosuppression effects resulted therefrom. As such, the present antibodies may treat diseases associated with the over activation of Siglec-3, such as hepatitis B virus (HBV) infection, neurodegenerative diseases, autoimmune diseases, or cancers. Accordingly, the present disclosure also includes methods for the treatment and / or prophylaxis of the above diseases.

The application discloses a recombinant glycoprotein targeting Siglec-9 and a preparation method and application thereof. The recombinant protein contains an amino acid sequence as shown in SEQ ID NO:1 or a sequence with more than 90% homology thereto. The recombinant protein targets and stimulates Siglec-9, serves as a Siglec-9 receptor stimulant, has strong binding force with Siglec-9, high activity, and has potential for treating excessive inflammatory diseases.

The present application relates to the field of biological medicine, and specifically provides an injection preparation of anti-Siglec-15 monoclonal antibody, the injection preparation comprising: anti-Siglec-15 monoclonal antibody; buffer salt; protein protective agent; surfactant; the pH value of the injection preparation is 5.5-7.5.The anti-Siglec-15 monoclonal antibody disclosed in the present application can be specifically combined with Siglec-15, effectively inhibit tumor growth, and be used for treating cancer or immunological diseases; secondly, the injection preparation provided in the present application provides a good storage microenvironment for anti-Siglec-15 monoclonal antibody through the synergistic cooperation of buffer solution, protein protective agent, osmotic pressure regulator, surfactant and the like in injection solution, effectively reduces the generation rate of aggregates or sub-visible particles, improves the physical stability of the antibody, ensures the biological activity of anti-Siglec-15 monoclonal antibody, and reduces potential safety risks.

This invention discloses a method for preparing a fusion protein of sialic acid-binding immunoglobulin-like lectin 6 extracellular fragment and human immunoglobulin G1-Fc fragment, and its application, belonging to the field of biomedical technology. The fusion protein consists of a functional fragment of the Siglec-6 extracellular region linked to the Fc fragment of human IgG1 via a peptide linker. Its amino acid sequence is selected from one of SEQ ID No. 1, SEQ ID No. 2, or SEQ ID No. 3, or a variant with more than 90% homology to the above sequences and retaining the biological activity of Siglec-6. The preparation method includes: cloning the Siglec-6 fragment and the coding sequence of the Fc fragment, constructing a recombinant expression plasmid and transfecting it into mammalian cells to induce expression, and purifying the target protein by affinity chromatography. The fusion protein vcSig6-Fc of this invention has extremely high structural stability and ligand binding affinity, can significantly inhibit the expression of inflammatory factors and matrix-degrading enzymes in chondrocytes, and shows excellent performance in promoting COL2A1 expression, thus exhibiting good protective effects on articular cartilage and therapeutic effects on rheumatoid arthritis.

This invention provides a pharmaceutical composition comprising an agent that can bind Siglec receptors on cell surface. This invention also provides the method of preparing said pharmaceutical composition and the use thereof.

The problem to be solved by the present invention is to overcome the unmet clinical need by providing improved compositions for the therapeutic treatment of patients.SOLUTION: The present invention relates to a Siglec-6 binding polypeptide comprising or consisting of an antibody or fragment thereof that binds to Siglec-6 or comprising or consisting of a Siglec-6 binding chimeric antigen receptor (CAR), a polynucleotide encoding the Siglec-6 binding polypeptide, an expression vector comprising the polynucleotide, an immune cell comprising the polypeptide, polynucleotide or expression vector, a method for producing the immune cell and a pharmaceutical composition comprising the immune cell. The immune cells and pharmaceutical compositions of the invention may be used in methods for treating a disease, such as cancer, in a patient.SELECTED DRAWING: None

The present invention relates to antibodies specifically binding to Siglec-15, an antigen-binding fragment thereof, and uses thereof. If the antibody or antigen-binding fragment thereof of the present invention is used, it is possible to obtain an excellent anticancer effect by effectively restoring the activity of inhibited T cells and inducing the death of cancer cells.

The invention discloses an inhibitory chimeric antigen receptor, comprising: an extracellular region for identifying a target protein; the N end of the transmembrane region is connected with the C end of the extracellular region; the transmembrane region comprises a terminal C and a terminal C, the terminal N of the intracellular region is connected with the terminal C of the transmembrane region, the intracellular region comprises an intracellular signal transduction structural domain, and the intracellular signal transduction structural domain is selected from an intracellular signal transduction structure in the following proteins: VISTA, CD200R, CD305, LILRB5, PSGL-1, SIGLEC-7, SIGLEC-9 or TMIGD2. After the inhibition type chimeric antigen receptor is combined with the target protein, the immune cell activity for expressing the inhibition type chimeric antigen receptor can be weakened or inhibited; immune cells simultaneously expressing the inhibited chimeric antigen receptor and the activated chimeric antigen receptor can specifically target target cells (such as tumor cells) based on NOT-gate logic, and non-target cells (such as normal cells) are prevented from being killed.

The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

Provided are Siglec-based chimeric polypeptides. Accordingly there is provided a chimeric receptor comprising: (a) an extracellular domain comprising an amino acid sequence of a Siglec-7 or a Siglec-9 receptor capable of binding a Siglec-7 and / or a Siglec-9 ligand; and (b) an intracellular domain comprising an amino acid sequence capable of transmitting a co-stimulatory signal in an immune cell expressing the chimeric receptor upon binding of said extracellular domain to said ligand. Also provided are polynucleotides encoding same, cells expressing same and methods of use thereof.